Pfizer (PFE) Retained Earnings (2009 - 2026)

Pfizer (PFE) has 18 years of Retained Earnings data on file, last reported at -$7.2 billion in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$7.2 billion, up 16.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.2 billion (up 16.06% YoY), and the FY2025 annual result was $114.6 billion, up 1561.49% from the prior year.
• Retained Earnings retreated to -$7.2 billion in Q1 2026 per PFE's latest filing, from $114.6 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $126.4 billion in Q4 2023 and troughed at -$8.6 billion in Q1 2025.
• A 5-year average of $29.4 billion and a median of -$7.8 billion in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings tumbled 108.04% in 2022, then soared 1636.91% in 2023.
• A 5-year view of Retained Earnings shows it stood at -$8.3 billion in 2022, then surged by 1525.25% to $118.4 billion in 2023, then plunged by 106.63% to -$7.8 billion in 2024, then soared by 1561.49% to $114.6 billion in 2025, then sank by 106.28% to -$7.2 billion in 2026.
• Business Quant data shows PFE's Retained Earnings at -$7.2 billion in Q1 2026, $114.6 billion in Q4 2025, and -$8.1 billion in Q3 2025.